Ensocell Ltd

Ensocell Ltd, based in Cambridge, UK, is a small, active company founded two years ago. It employs five people and holds £1,637,361 in assets. With seven directors and no reported owners, the company operates from a real address shared by only one other business. It’s an irregular importer, primarily dealing in miscellaneous chemical products, with its last import operation occurring in January 2025.

The company’s website reveals it's a venture capital-backed Life Science company focused on single-cell genomics, spatial genomics, AI, and drug discovery. Founded by scientists from the Wellcome Sanger Institute, Ensocell operates from the Wellcome Genome Campus in Hinxton, UK, and Alameda, California, USA. It’s actively seeking talented individuals to join its team, emphasizing a mission to decode human disease biology and develop precision therapeutics. The company’s website also highlights its research and experimental development in biotechnology industries.

Financially, Ensocell Ltd shows some concerning trends. Accumulated depreciation for property, plant, and equipment has grown significantly, increasing by 240% to £3,900. While cash bank on hand has increased by 76% to £910,000, creditors have risen sharply by 140% to £180,000. Debtors have also increased substantially, growing by 440% to £730,000. Equity, however, has decreased by 110% to -£3.2 million. The company’s small size—meeting two of three conditions for being classified as small—helps it remain nimble, but the significant decrease in equity suggests it’s burning through money. The lack of an auditor mentioned, likely due to its small size, means the figures are unaudited. The company’s reliance on venture capital backing may be sustaining it for now, but the financial data indicates a need for careful management.

Registered in England/Wales under the registration number 14714531, with a registered address at CB10 1DR, England, Cambridge, Biodata Innovation Centre, Wellcome Genome Campus.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.